Poor kidney allograft survival associated with positive B cell – Only flow cytometry cross matches: A ten year single center study

• Published in: Human immunology Vol. 74; no. 10; pp. 1304 - 1312
• Main Authors: Norin, Allen J, Mondragon-Escorpizo, Mary O, Brar, Amarpali, Hochman, David, Sumrani, Nabil, Distant, Dale A, Salifu, Moro O
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-10-2013
• Subjects: Adult; Allergy and Immunology; Antibodies - blood; Antibodies - immunology; B-Lymphocytes - immunology; B-Lymphocytes - metabolism; Female; Flow Cytometry; Graft Rejection - immunology; Graft Survival - immunology; Histocompatibility Testing - methods; HLA Antigens - immunology; Humans; Kidney Transplantation - adverse effects; Male; Middle Aged; Risk Factors; T-Lymphocytes - immunology; T-Lymphocytes - metabolism; Tissue Donors; Transplantation, Homologous; DD; Flow cytometry; donor specific antibodies; anti-thymocyte globulin; IDDM; Black African Americans; HR; DS; FCXM; DSA; complement dependent cytotoxicity cross matches (CDCXM); decease donor; insulin dependent diabetes mellitus; AA; MP; single antigen beads; CDCXM; methylprednisolone; AR; hazard ratios; acute rejection; ATG; SAB; MCS; FC; donor specific; Flow cytometry cross match; mean channel shift
• ISSN: 0198-8859; 1879-1166
• DOI: 10.1016/j.humimm.2013.06.027

Abstract The presence of donor specific antibody (DSA) to class 1 or class 2 HLA as detected respectively in T cell or B cell – only flow cytometry cross matches (FCXMs) are risk factors for renal allograft survival, though the comparative risk of these XMs has not been definitively established. Allograft survival and FCXM data in 624 microcytotoxicity (CDC) XM negative kidney transplants were evaluated. Short and long term allograft survival was significantly less in recipients with T− B+ FCXMs (1 year, 74%, 10 year, 58%) compared to T+ B+ FCXMs (1 year, 84%, 10 year, 68%) and to T− B− FCXM (1 year, 90%, 10 year, 85%). Risk factors were positive FCXM, deceased donor (DD) transplantation and donor age, but not race, gender, recipient age or previous transplant. Recipients with T− B+ and T+ B+ FCXMs were at 4.5 and 2.5 fold greater risk, respectively, of DD allograft failure compared to patients with T− B− FCXMs. The quantitative value of FCXM did not correlate with the duration of graft survival. We conclude that patients with DSA to class 2 HLA have a greater risk of early and late allograft failure compared to patients with DSA to class 1 HLA.